Tao Pei, PhD

Dr. Tao Pei joined Arrowhead Pharmaceuticals in 2014 and currently serves as Chief Scientific Officer.

Dr. Pei joined Arrowhead as Director of Chemistry and was promoted to Vice President of Discovery Chemistry in 2019. In February 2026, he was appointed Chief Scientific Officer. He is an accomplished scientist with deep expertise spanning discovery chemistry and process development.

Dr. Pei is a key architect of Arrowhead’s proprietary TRiM™ technology platform and contributed to the final design of the company’s first TRiM™ preclinical candidate, Olpasiran. As Head of Discovery Chemistry, he built and led multiple functional groups focused on advancing TRiM™ platforms for targeted siRNA delivery beyond the liver, expanding into extrahepatic tissues including the central nervous system, skeletal muscle, adipose tissue, heart, eye, and lung.

Prior to joining Arrowhead, Dr. Pei held roles in Process Research at Merck and at Merck Sirna Therapeutics, where he worked on RNAi delivery technologies and small-molecule process chemistry. He earned his Ph.D. in Chemistry from Duke University.

RNAi is a once-in-a-generation revolution in medicine. Every step forward unlocks the possibility of treating diseases once thought untouchable — and brings real hope to patients still waiting for answers.